+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment



The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment



Journal of Osteoporosis 2014: 607145



This trial was conducted to investigate the long-term effects of proton pump inhibitor (PPI) coadministration on the efficacy of weekly risedronate treatment for osteoporosis. Ninety-six women over 50 years old with low bone mineral density (BMD) participated in this trial. Subjects were randomly divided into 2 groups: a 17.5 mg dose of sodium risedronate was administered weekly, with or without a daily 10 mg dose of sodium rabeprazole (n = 49 and 47 in the BP + PPI and BP groups, resp.). The following biomarkers were measured at the baseline and every 3 months: bone-specific alkaline phosphatase, N-terminal telopeptide of type I collagen corrected for creatinine, parathyroid hormone, BMD of the lumbar spine, and physical parameters evaluated according to the SF-36v2 Health Survey. Statistical comparisons of these parameters were performed after 6, 12, 18, and 24 months. The Δ values of improvement in physical functioning after 12 months and bodily pain after 6 and 12 months in the BP + PPI group were significantly larger than those in the BP group. These results suggest that PPI does not adversely affect bone metabolism. Alternatively, approved bone formation by concomitant PPI treatment may have had favorable effects on the improvement of bodily pain and physical functions.

(PDF emailed within 0-6 h: $19.90)

Accession: 059112456

Download citation: RISBibTeXText

PMID: 25436170

DOI: 10.1155/2014/607145


Related references

The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. Journal of Bone and Mineral Metabolism 31(2): 206-211, 2013

Assessing Human Health PM 2.5 and Ozone Impacts from U.S. Oil and Natural Gas Sector Emissions in 2025. Environmental Science and Technology 52(15): 8095-8103, 2018

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. Journal of Bone and Mineral Research 20(1): 141-151, 2004

Pharmacology and therapeutic effectiveness of the proton pump inhibitor omeprazole. Acta Physiologica Scandinavica Supplementum 0(608): 38, 1992

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metabolism and Disposition: the Biological Fate of Chemicals 39(11): 2020-2033, 2012

Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(12): E64, 2014

Retraction. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(29): 399-399, 2015

Comparison of concurrent treatment with vitamin K 2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Journal of Bone and Mineral Metabolism 35(4): 385-395, 2016

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporosis International 24(1): 301-310, 2013

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. 2012

Therapeutic and cost effectiveness of proton pump inhibitor regimens for idiopathic or drug-induced peptic ulcer complication. Archives of Pharmacal Research 34(3): 443-449, 2011

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. Journal of Clinical Endocrinology and Metabolism 91(7): 2631-2637, 2006

Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric 9(2): 129-134, 2006

Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clinical Gastroenterology and Hepatology 10(4): 338-45; Quiz E39-40, 2012

Acid-related diseases. What is the current rescue treatment of choice for Helicobacter pylori: quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?. Gastroenterologia Y Hepatologia 31(6): 400-401, 2008